Op2Lysis is excited to announce the receipt of public funding from the Normandy Region and the 🇪🇺 FEDER FSE+ FTJ Normandie program for its THROMBO-STROKE collaborative project. Running from October 2024 to September 2027, the project aims to develop innovative models for ischemic stroke ⚡🧠 by addressing the critical challenge of clot heterogeneity. In collaboration […]
24 July 2024 💥We are delighted to announce that the O2L-001 technology developed by Op2Lysis to treat massive and deep cerebral haemorrhage 🩸🧠 has reached a new milestone. The first “Dose Range Finding” safety study has produced very positive results. This success means that highly effective doses can be used in clinical trials.
There are still a few days left to wish a very Happy New Year 2024 to our community, our investors, our readers and all those who make the Op2Lysis program live, progress and bring new hope to hemorrhagic stroke patients every day 🧓🧠🩸. We are therefore delighted to share with you the progress made in […]